Business Context and Reporting Period
This Form 8-K filing by Biorestorative Therapies, Inc. (a Delaware corporation and emerging growth company) reports unregistered sales of equity securities and debt transactions occurring between November 6, 2019, and November 20, 2019. The report was filed on November 20, 2019, with the earliest event reported on November 6, 2019.
Key Financial Metrics and Transactions
The filing details specific capital raising and debt restructuring activities rather than standard operating financial metrics such as revenue or net income.
- Debt-for-Equity Swap: Issued 3,076,504 shares of common stock to settle $80,873 of outstanding indebtedness (including accrued interest).
- Debt Repayment: Repaid $99,195 in outstanding promissory notes (including accrued interest).
- Convertible Note Issuance: Issued a $110,250 principal convertible note for $100,000 in cash proceeds. The note bears 12% annual interest, matures in November 2020, and is convertible at 58% of the fair value of common stock after six months.
- Equity and Warrant Issuance: Issued 142,857 shares of common stock and a five-year vested warrant for 142,857 shares (exercise price $0.10) for $10,000 in gross proceeds.
Material Changes Versus Prior Period
The filing does not provide comparative financial data or a discussion of material changes in operating performance versus prior periods. The document focuses exclusively on discrete financing events occurring in November 2019.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of the securities' terms. The transactions were conducted under Section 4(a)(2) and Section 3(a)(9) of the Securities Act of 1933, relying on the belief that investors were accredited and had access to the company's financial reports (10-K and 10-Q filings).
Investor Verification Checklist
- Verify the dilution impact of the 3,219,361 total shares issued (3,076,504 for debt + 142,857 for cash) on existing shareholders.
- Confirm the terms of the new convertible note, specifically the 58% conversion discount and the $100,000 cash proceeds received.
- Review the company's cash position post-transaction, noting the net cash inflow of approximately $10,000 from the equity/warrant sale and $100,000 from the note, offset by the $99,195 debt repayment.
- Check the company's latest 10-Q filings to understand the total outstanding indebtedness prior to these November transactions.